Corbus Pharmaceuticals Holdings Inc. (CRBP) Expected to Post FY2016 Earnings of ($0.39) Per Share
Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) – Investment analysts at Cantor Fitzgerald issued their FY2016 EPS estimates for shares of Corbus Pharmaceuticals Holdings in a report issued on Monday. Cantor Fitzgerald analyst E. Piros anticipates that the brokerage will post earnings of ($0.39) per share for the year. Cantor Fitzgerald has a “Buy” rating and a $17.00 price target on the stock. Cantor Fitzgerald also issued estimates for Corbus Pharmaceuticals Holdings’ FY2017 earnings at ($0.48) EPS.
Separately, Aegis reissued a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a report on Sunday, August 21st.
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) traded down 1.86% on Wednesday, reaching $9.50. 894,559 shares of the company’s stock traded hands. The firm has a 50-day moving average price of $6.21 and a 200-day moving average price of $3.60. Corbus Pharmaceuticals Holdings has a 52 week low of $1.01 and a 52 week high of $10.78. The stock’s market capitalization is $415.61 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/corbus-pharmaceuticals-holdings-inc-crbp-expected-to-post-fy2016-earnings-of-0-39-per-share.html
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last posted its earnings results on Monday, August 15th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by $0.03. Corbus Pharmaceuticals Holdings had a negative net margin of 890.44% and a negative return on equity of 107.10%.
In related news, CFO Sean F. Moran purchased 30,800 shares of the firm’s stock in a transaction on Thursday, September 8th. The stock was bought at an average cost of $5.12 per share, with a total value of $157,696.00. Following the completion of the acquisition, the chief financial officer now owns 330,110 shares of the company’s stock, valued at approximately $1,690,163.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Barbara White purchased 38,000 shares of the firm’s stock in a transaction on Wednesday, August 17th. The stock was bought at an average cost of $3.15 per share, with a total value of $119,700.00. Following the completion of the acquisition, the insider now directly owns 161,067 shares of the company’s stock, valued at approximately $507,361.05. The disclosure for this purchase can be found here. 11.60% of the stock is owned by company insiders.
About Corbus Pharmaceuticals Holdings
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases.
Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.